

Samsung Biologics launches drug screening services, Samsung Organoids

16 June 2025 | News

Samsung Organoids to provide data-driven analysis of candidate molecules



South Korea-based Samsung Biologics, a leading contract development and manufacturing organisation (CDMO), has announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug discovery and development.

Organoids are three-dimensional cell culture systems engineered to closely mimic human organs, offering clinically relevant insights to better understand specific drug responses and improve lead selection. Organoids are emerging as a new research model due to their high similarity to live tissues and potential applications in biomarker discovery and drug efficacy prediction.

Samsung Organoids support precision screening to predict patient responses, streamline preclinical development, and accelerate timelines toward investigational new drug (IND) filings through data-driven analysis of candidate molecules.

With the launch, Samsung Biologics expands its business to include preclinical research, with service offerings spanning target discovery, lead selection, preclinical development, and clinical trial planning. Leveraging its expertise in development and manufacturing, the company will provide data-driven, multi-modal insights into the characteristics and mechanisms of candidate molecules. By helping clients address challenges that may arise during the drug discovery phase, Samsung Biologics aims to enhance clinical success rates.

"The latest service launch reflects our unwavering commitment to driving innovation by improving drug success rates and

creating new possibilities in personalised medicine," said John Rim, CEO and President of Samsung Biologics. "The addition of research services is a significant move for us to create added value for clients by supporting the drug life cycle from start to finish with thorough therapeutic analysis."